RANK (Receptor Activator of Nuclear Factor kappa B) and RANK Ligand Are Expressed in Giant Cell Tumors of Bone
Open Access
- 1 February 2002
- journal article
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 117 (2) , 210-216
- https://doi.org/10.1309/bpet-f2pe-p2bd-j3p3
Abstract
In giant cell tumors of bone (GCTBs), the mesenchymal stromal cells are the neoplastic cells and induce recruitment and formation of osteoclasts (OCsKeywords
This publication has 12 references indexed in Scilit:
- Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of boneBone, 2001
- Expression of Osteoclast Differentiation Signals by Stromal Elements of Giant Cell TumorsJournal of Bone and Mineral Research, 2000
- The Roles of Osteoprotegerin and Osteoprotegerin Ligand in the Paracrine Regulation of Bone ResorptionJournal of Bone and Mineral Research, 2000
- Localization of RANKL (receptor activator of NFκB ligand) mRNA and protein in skeletal and extraskeletal tissuesBone, 1999
- RANK Is the Essential Signaling Receptor for Osteoclast Differentiation Factor in OsteoclastogenesisBiochemical and Biophysical Research Communications, 1998
- Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and ActivationCell, 1998
- Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone DensityCell, 1997
- Evidence for an autocrine/paracrine role for interleukin-6 in bone resorption by giant cells from giant cell tumors of bone.Endocrinology, 1992
- OSTEOBLASTIC CELLS ARE INVOLVED IN OSTEOCLAST FORMATIONEndocrinology, 1988
- Human giant cell tumors of bone identification and characterization of cell types.Journal of Clinical Investigation, 1987